Related Experiment Video
Updated: Jul 6, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Severe liver disease in pregnancy
Hui Chen1, Li Yuan, Jianping Tan
1Obstetrics and Gynecology Department, The Second Affiliated Hospital of Sun Yat-Sen University, Guangdong, China.
Summary
Fulminant hepatitis of pregnancy (FHP) and acute fatty liver of pregnancy (AFLP) present similar symptoms but require different management. Early diagnosis is crucial for better pregnancy outcomes in these severe liver conditions.
Area of Science:
- Hepatology
- Obstetrics
- Maternal-Fetal Medicine
Background:
- Fulminant hepatitis of pregnancy (FHP) and acute fatty liver of pregnancy (AFLP) are severe liver diseases unique to pregnancy.
- These conditions pose significant risks to both maternal and fetal health.
Purpose of the Study:
- To delineate the clinical features of FHP and AFLP.
- To investigate the association between these liver conditions and pregnancy outcomes.
Main Methods:
- A comparative study involving 55 pregnant women diagnosed with severe liver disease.
- Categorization into 41 cases of FHP and 14 cases of AFLP.
Main Results:
- Jaundice and hepatic encephalopathy were common manifestations and complications in both FHP and AFLP.
- Disseminated intravascular coagulation, albuminuria, and prothrombin activity were identified as independent risk factors for maternal mortality.
- FHP cases exhibited lower rates of preterm labor, fetal demise, and neonatal asphyxia compared to AFLP.
Conclusions:
- Both FHP and AFLP are associated with severe maternal complications and adverse pregnancy outcomes.
- Distinct management strategies for FHP and AFLP underscore the critical need for accurate and early diagnosis to optimize patient care and outcomes.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...